Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

nt with Janssen, total amounts in excess of the annual cap ("Excess Amounts") plus interest may not exceed $225 million.

The Company has recognized the Excess Amounts as a reduction to operating expenses in the current year as the Company's repayment of the Excess Amounts to Janssen is contingent and would become payable only after the third profitable calendar quarter for the product under the collaboration. Further, the Excess Amounts shall be reimbursable only from the Company's share of future full calendar quarter pre-tax profits (if any) after the third profitable calendar quarter for the product under the collaboration.

For the calendar year ended December 31, 2012, the Company's total share of collaboration expenses under the Agreement was $68.1 million. As of December 31, 2012, total Excess Amounts totaled $18.1 million, of which during the quarter ended December 31, 2012, $17.3 million was recorded as a reduction to research and development expense and $0.8 million was recorded as a reduction to general and administrative expense.

GAAP operating expenses were $40.6 million for the six months ended December 31, 2012, compared to $30.6 million for the six months ended December 31, 2011. Included in operating expenses for the six months ended December 31, 2012 is the $18.1 million reduction to operating expenses for Excess Amounts.

GAAP operating expenses were $16.7 million for the quarter ended December 31, 2012, compared to $16.0 million for the quarter ended December 31, 2011 and $23.9 million for the quarter ended September 30, 2012. Included in operating expenses for the quarter ended December 31, 2012 is the $18.1 million reduction to operating expenses for the Excess Amounts.

At December 31, 2012, the Company had cash, cash equivalents and marketable securities of $317.1 million, compared with $203.6 million at June 30, 2012. In addition, as of December 31, 2012, the Company had $26.6 million receivable from Jansse
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... (PRWEB) September 30, 2014 New applications ... arrangements that have evolved in nature over millennia are ... bioinspired materials for applications in biophotonics in the ... . The journal is published by SPIE, the international ... Library. Several of the peer-reviewed articles are accessible via ...
(Date:10/1/2014)... -- This report analyzes the worldwide markets ... the following Product Segments: Proteases, Polymerases, Carbohydrases, ... also analyzed are Pharmaceuticals & Diagnostics, Research/Biotechnology, ... separate comprehensive analytics for the US, Canada, ... America. Annual estimates and forecasts are provided ...
(Date:9/30/2014)... analog of one of nature,s most efficient light-harvesting ... led by Alejandro Briseno of the University of ... developing long-sought polymer architecture to boost power-conversion efficiency ... devices. , Briseno, with colleagues and graduate ... University and Dresden University of Technology, Germany, report ...
(Date:9/30/2014)... Over the last decade, the laboratory filtration market is ... increased acceptance of new filtration technologies in end users ... also catalyzing the growth of laboratory filtration market. , ... at a strong CAGR during the forecast period of ... by 2019. The market is mainly driven by the ...
Breaking Biology Technology:Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 2Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 3Global Specialty Enzymes Industry 2Global Specialty Enzymes Industry 3Global Specialty Enzymes Industry 4Global Specialty Enzymes Industry 5Global Specialty Enzymes Industry 6Global Specialty Enzymes Industry 7Global Specialty Enzymes Industry 8Global Specialty Enzymes Industry 9Global Specialty Enzymes Industry 10Global Specialty Enzymes Industry 11Global Specialty Enzymes Industry 12Global Specialty Enzymes Industry 13Global Specialty Enzymes Industry 14Global Specialty Enzymes Industry 15Global Specialty Enzymes Industry 16Global Specialty Enzymes Industry 17Global Specialty Enzymes Industry 18Global Specialty Enzymes Industry 19Global Specialty Enzymes Industry 20Global Specialty Enzymes Industry 21Global Specialty Enzymes Industry 22Global Specialty Enzymes Industry 23Global Specialty Enzymes Industry 24Global Specialty Enzymes Industry 25Global Specialty Enzymes Industry 26Blades of grass inspire advance in organic solar cells 2Blades of grass inspire advance in organic solar cells 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 4Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 5
... Isis,Pharmaceuticals, Inc. (Nasdaq: ISIS ) today announced ... Parshall, J.D. to Chief Operating Officer,effective immediately. Ms. ... is a Director of the Company., "This ... Lynne,s responsibilities at Isis," commented Stanley Crooke, M.D.,Ph.D., ...
... WuXi PharmaTech (NYSE:,WX), China,s premier provider of ... Deval L. Patrick of the Commonwealth of,Massachusetts, ... Official Delegation, paid a visit to the ... (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ), Massachusetts ...
... Pharmaceutical announced,today that the Avon Foundation Breast Cancer ... to conduct multicenter clinical studies,focused on measuring levels ... and tissue samples from breast cancer patients. Results ... a blood test that would,enable early detection of ...
Cached Biology Technology:Isis Announces Appointment of B. Lynne Parshall as Chief Operating Officer 2Isis Announces Appointment of B. Lynne Parshall as Chief Operating Officer 3Massachusetts Governor Deval L. Patrick Pays Visit to WuXi PharmaTech 2Massachusetts Governor Deval L. Patrick Pays Visit to WuXi PharmaTech 3A&G Pharmaceutical Receives $870,000 Grant from Avon Foundation to Advance Innovative Blood Diagnostic Test for Early Detection of Breast Cancer 2A&G Pharmaceutical Receives $870,000 Grant from Avon Foundation to Advance Innovative Blood Diagnostic Test for Early Detection of Breast Cancer 3
(Date:9/30/2014)... N.C. -- Pollution in urban and farm runoff in ... new study finds. , The study, published Tuesday ... that nitrogen in the runoff ends up in algae ... on the animals, eyes, flippers and internal organs. , ... the National Oceanic and Atmospheric Administration (NOAA) conducted the ...
(Date:9/30/2014)... hope: A new research report published in October 2014 ... explains how scientists developed a synthetic version of a ... in human and mouse eggs similar to the natural ... fertilization. , "We believe that the results of this ... of human fertilization by providing a precise answer to ...
(Date:9/30/2014)... People who suffer from asthma may think there,s ... asthma besides properly taking medications and avoiding allergic triggers. ... Annals of Allergy, Asthma and Immunology , the ... and Immunology (ACAAI), asthma sufferers can learn lessons about ... described in the Annals article improved her asthma once ...
Breaking Biology News(10 mins):Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3Synthetic sperm protein raises the chance for successful in vitro fertilization 2Asthma symptoms kicking up? Check your exposure to air pollution 2
... Environmental Research UFZ present CLIMBER: Climatic niche ... dataset on the climatic niche characteristics of 397 European ... information provided in this dataset is of great relevance ... of high quality standards and open access, data ready ...
... fins with self-adaptive flaps, the feathers on a diving peregrine ... a study published in PLOS ONE on February ... and Fluid Dynamics in Germany and colleagues., Peregrine falcons are ... to 200 miles per hour when diving. Scientists studying the ...
... 6, 2014 -- Advances in neonatal care for very ... for these fragile infants. However, preterm infants have ... serious lung disease, which is a major cause of ... scheduled for publication in The Journal of Pediatrics ...
Cached Biology News:Unique new dataset CLIMBER: Climatic niche characteristics of the butterflies in Europe 2Stem cells to treat lung disease in preterm infants 2
Recombinant Mouse Wnt-3a...
... at least 20 structurally and functionally related ... superfamily. BMPs were originally identified as protein ... are also involved in embryogenesis and morphogenesis ... the growth, differentiation, chemotaxis and apoptosis of ...
RABBIT ANTI HUMAN TRRAP (CT) Immunogen: Recombinant C-terminal kinase-related domain of human TRRAP....
RABBIT ANTI HUMAN CHYMOTRYPSIN...
Biology Products: